Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Bimzelx Prior Authorization Update | OpenPay…
    Ask Trek AI about this page
    ModifiedCignaPolicy IP0658

    Bimzelx Prior Authorization Policy

    Customize your policy alerts

    Sign up for Cigna Policy IP0658 alerts

    Get alerted when Policy IP0658 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-necessity criteria for Bimzelx in adults with ankylosing spondylitis, hidradenitis suppurativa, non-radiographic axial spondyloarthritis, plaque psoriasis, or psoriatic arthritis.

    Policy Summary
    PayerCigna
    PolicyBimzelx Prior Authorization Policy
    Policy CodePolicy IP0658
    Change TypeModified
    Effective DateNov 15, 2026
    Last ReviewOct 30, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization with the covered indication, patient age, specialist involvement, risk evaluation, and applicable clinical documentation.
    SourceLink
    POLICY UPDATE CHANGES

    Criteria for ankylosing spondylitis and non-radiographic axial spondyloarthritis were added to the policy.

    Criteria for psoriatic arthritis and hidradenitis suppurativa were added to the policy.

    Plaque psoriasis requirements were added addressing evaluation of suicidal ideation or behavior, depression, and relevant history for initial and ongoing Bimzelx therapy.

    The suicidal-risk and depression requirements were revised to state that, according to the prescriber, the patient has been evaluated for risks versus benefits and does not have moderately severe to severe depression.

    A 3-month trial or prior intolerance to Otezla, Otezla XR, or Sotyktu was added as an exception to the plaque psoriasis requirement for a trial of one traditional systemic agent.

    The plaque psoriasis methotrexate contraindication requirement was revised to specify that, according to the prescriber, the patient has a contraindication to methotrexate.

    Icotyde and tofacitinib generics were added to the appendix.

    5

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    FDA-approved covered indications
    RequiredPrior authorization for Bimzelx
    3 or 6 monthsInitial approval duration
    1 yearContinuation approval duration
    2Not-medically-necessary use categories

    Covered Indications and Medical Necessity

    Ankylosing Spondylitis

    Covered when ONE of the following is met.

    Ankylosing spondylitis

    • Initial therapy: Approve for 6 months when the patient is older than 18 years; the prescriber has evaluated suicidal ideation or behavior risks versus benefits; the patient does not have moderately severe to severe depression; the patient has no history of suicidal ideation or suicidal behavior within the past 5 years; and the medication is prescribed by or in consultation with a rheumatologist.
    • Continuation therapy: Approve for 1 year when the patient has been established on therapy for at least 6 months; the prescriber has evaluated suicidal ideation or behavior risks versus benefits; the patient does not have moderately severe to severe depression; the patient does not have suicidal ideation or suicidal behavior; and the patient has either a beneficial clinical response from baseline on at least one objective measure or improvement in at least one symptom, such as pain, stiffness, function, or activities of daily living.Established for ≥6 months

      Patients with less than 6 months of therapy or who are restarting therapy are reviewed under initial-therapy criteria.

    Hidradenitis Suppurativa

    Covered when ONE of the following is met.

    Hidradenitis suppurativa

    • Initial therapy: Approve for 3 months when the patient is at least 18 years old; has tried at least one other therapy; the prescriber has evaluated suicidal ideation or behavior risks versus benefits; the patient does not have moderately severe to severe depression; the patient has no history of suicidal ideation or suicidal behavior within the past 5 years; and the medication is prescribed by or in consultation with a dermatologist.At least 1 prior therapy

      Examples of prior therapy include intralesional or oral corticosteroids, systemic antibiotics, and isotretinoin.

    • Continuation therapy: Approve for 1 year when the patient has been established on Bimzelx for at least 3 months; the prescriber has evaluated suicidal ideation or behavior risks versus benefits; the patient does not have moderately severe to severe depression; the patient does not have suicidal ideation or suicidal behavior; an objective assessment shows a beneficial response from baseline; and at least one symptom has improved from baseline, such as pain or drainage of lesions, nodules, or cysts.Established for ≥3 months

    Non-Radiographic Axial Spondyloarthritis

    Covered when ONE of the following is met.

    Non-radiographic axial spondyloarthritis

    • Initial therapy: Approve for 6 months when the patient is older than 18 years; has objective signs of inflammation shown by C-reactive protein elevated beyond the reporting laboratory's upper limit of normal and/or sacroiliitis reported on magnetic resonance imaging; the prescriber has evaluated suicidal ideation or behavior risks versus benefits; the patient does not have moderately severe to severe depression; the patient has no history of suicidal ideation or suicidal behavior within the past 5 years; and the medication is prescribed by or in consultation with a rheumatologist.CRP above the reporting laboratory upper limit of normal and/or MRI-reported sacroiliitis
    • Continuation therapy: Approve for 1 year when the patient has been established on therapy for at least 6 months; the prescriber has evaluated suicidal ideation or behavior risks versus benefits; the patient does not have moderately severe to severe depression; the patient does not have suicidal ideation or suicidal behavior; and the patient has either a beneficial clinical response from baseline on at least one objective measure or improvement in at least one symptom, such as pain, stiffness, function, or activities of daily living.Established for ≥6 months

    Plaque Psoriasis

    Covered when ONE of the following is met.

    Plaque psoriasis

    • Initial therapy: Approve for 3 months when the patient is at least 18 years old; has either tried at least one traditional systemic agent for psoriasis for at least 3 months unless intolerant, completed a qualifying 3-month trial of or had prior intolerance to another biologic, Icotyde, Otezla/Otezla XR, or Sotyktu, or has a prescriber-documented contraindication to methotrexate; the prescriber has evaluated suicidal ideation or behavior risks versus benefits; the patient does not have moderately severe to severe depression; the patient has no history of suicidal ideation or suicidal behavior within the past 5 years; and the medication is prescribed by or in consultation with a dermatologist.Traditional systemic-agent trial ≥3 months unless intolerant

      Examples of traditional systemic agents include methotrexate, cyclosporine, and acitretin; a 3-month PUVA trial also counts. A biosimilar of the requested biologic does not satisfy the qualifying alternative-therapy exception.

    • Continuation therapy: Approve for 1 year when the patient has been established on therapy for at least 3 months; the prescriber has evaluated suicidal ideation or behavior risks versus benefits; the patient does not have moderately severe to severe depression; the patient does not have suicidal ideation or suicidal behavior; objective assessment shows improvement from baseline in body surface area, erythema, induration or thickness, and/or scale; and at least one symptom has improved from baseline, such as pain, itching, or burning.

    Psoriatic Arthritis

    Covered when ONE of the following is met.

    Psoriatic arthritis

    • Initial therapy: Approve for 6 months when the patient is older than 18 years; the prescriber has evaluated suicidal ideation or behavior risks versus benefits; the patient does not have moderately severe to severe depression; the patient has no history of suicidal ideation or suicidal behavior within the past 5 years; and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.
    • Continuation therapy: Approve for 1 year when the patient has been established on therapy for at least 6 months; the prescriber has evaluated suicidal ideation or behavior risks versus benefits; the patient does not have moderately severe to severe depression; the patient does not have suicidal ideation or suicidal behavior; and the patient has either a beneficial clinical response from baseline on at least one objective measure or improvement in at least one symptom, such as joint pain, morning stiffness, fatigue, function, activities of daily living, or soft-tissue swelling.Established for ≥6 months

      Patients with less than 6 months of therapy or who are restarting therapy are reviewed under initial-therapy criteria.

    Concurrent administration of Bimzelx with another biologic used for an inflammatory condition or with a targeted synthetic oral small-molecule drug is not medically necessary. This exclusion does not apply to conventional synthetic DMARDs, including methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine.

    Use of Bimzelx for inflammatory bowel disease, including Crohn's disease or ulcerative colitis, is not medically necessary.

    Bimzelx use for indications other than the five covered FDA-approved indications—ankylosing spondylitis, hidradenitis suppurativa, non-radiographic axial spondyloarthritis, plaque psoriasis, and psoriatic arthritis—is considered not medically necessary.

    Clinical Documentation Elements

    C-reactive protein
    DefinitionC-reactive protein elevated beyond the upper limit of normal for the reporting laboratory.
    Objective clinical response
    DefinitionBeneficial clinical response from baseline, assessed by at least one objective measure and/or improvement in at least one symptom, as specified by the indication.
    Examples of symptomsDecreased pain or stiffness, improved function or activities of daily living, and decreased soft-tissue swelling where applicable.

    Authorization, Sequencing, and Documentation

    Prior Authorization

    Prior Authorization and Specialist Requirement

    Prior authorization is required for Bimzelx benefit coverage. Initial approval requires prescribing by, or consultation with, a physician who specializes in the condition being treated.

    Step Therapy

    Preferred Product Sequencing

    Use applicable preferred products before requesting Bimzelx, unless an exception under the applicable Cigna preferred specialty management policy applies.

    Step Therapy

    Document Indication-Specific Prior Therapy

    Confirm that the request meets the indication-specific prior-treatment requirements before submission. Requirements differ by FDA-approved indication.

    Bimzelx Policy Overview

    Bimzelx (bimekizumab-bkzx) is an interleukin-17A and interleukin-17F blocker. This policy addresses coverage and prior authorization for adults with active ankylosing spondylitis, moderate-to-severe hidradenitis suppurativa, active non-radiographic axial spondyloarthritis with objective inflammation, moderate-to-severe plaque psoriasis in candidates for systemic therapy or phototherapy, and active psoriatic arthritis. The policy also requires evaluation of suicidal ideation and behavior risk because Bimzelx carries a warning or precaution concerning suicidal ideation and behavior.

    Policy Definitions

    Objective signs of inflammation
    C-reactive proteinElevated beyond the upper limit of normal for the reporting laboratory.
    Magnetic resonance imagingSacroiliitis reported on magnetic resonance imaging.
    Currently receiving Bimzelx
    Established therapyThe patient has met the indication-specific minimum established-therapy period: 6 months for ankylosing spondylitis, non-radiographic axial spondyloarthritis, or psoriatic arthritis; 3 months for hidradenitis suppurativa or plaque psoriasis.
    Less than the required periodA patient who has received less than the required established-therapy period is reviewed under the indication's initial-therapy criteria.
    Restarting treatmentA patient who is restarting Bimzelx is reviewed under the indication's initial-therapy criteria.

    Initial Approval Requirements

    Initial Therapy Criteria

    Initial approval requires the applicable indication-specific requirements and all safety and specialist requirements below.

    Initial therapy requirements

    • Indication and approval duration

      • Ankylosing spondylitis, non-radiographic axial spondyloarthritis, or psoriatic arthritis: The requested indication is ankylosing spondylitis, non-radiographic axial spondyloarthritis, or psoriatic arthritis; approve for 6 months when the applicable indication-specific clinical requirements are met.
      • Hidradenitis suppurativa or plaque psoriasis: The requested indication is hidradenitis suppurativa or plaque psoriasis; approve for 3 months when the applicable indication-specific clinical requirements are met.
    • Safety and specialist requirements:

    Continuation Approval Requirements

    Continuation Criteria

    Continuation approval is generally for 1 year after the applicable minimum established-therapy period.

    Common continuation requirements: The prescriber has evaluated suicidal ideation or behavior risks versus benefits; the patient does not have moderately severe to severe depression; the patient does not have suicidal ideation or suicidal behavior; and the patient demonstrates the indication-specific clinical response from baseline required by the policy.Established for ≥6 months for ankylosing spondylitis, non-radiographic axial spondyloarthritis, and psoriatic arthritis; ≥3 months for hidradenitis suppurativa and plaque psoriasis

    Patients who have received less than the applicable established-therapy period or who are restarting Bimzelx are reviewed under the indication's initial-therapy criteria. The required response may be an objective beneficial response and/or improvement in at least one indication-specific symptom.

    Required Prior Therapy

    StepRequirement
    1Use preferred products before Bimzelx approval according to the applicable Cigna Inflammatory Conditions Preferred Specialty Management Policy, subject to that policy’s exceptions.
    StepRequirement
    2For hidradenitis suppurativa, the patient must have tried at least one other therapy, such as intralesional or oral corticosteroids, systemic antibiotics, or isotretinoin.
    StepRequirement
    3For plaque psoriasis, try at least one traditional systemic agent—such as methotrexate, cyclosporine, or acitretin—for at least 3 months unless intolerant; a 3-month PUVA trial also counts. The requirement may be bypassed after a 3-month trial or previous intolerance to another biologic, Icotyde, Otezla/Otezla XR, or Sotyktu, or when the prescriber documents a methotrexate contraindication. A biosimilar of the requested biologic does not count.
    Policy Summary
    PayerCigna
    PolicyBimzelx Prior Authorization Policy
    Policy CodePolicy IP0658
    Change TypeModified
    Effective DateNov 15, 2026
    Last ReviewOct 30, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization with the covered indication, patient age, specialist involvement, risk evaluation, and applicable clinical documentation.
    SourceLink
    On This Page
    Covered Indications and Medical NecessityClinical Documentation ElementsAuthorization, Sequencing, and DocumentationBimzelx Policy OverviewPolicy DefinitionsInitial Approval RequirementsContinuation Approval RequirementsRequired Prior Therapy

    Patients with less than 3 months of therapy or who are restarting therapy with Bimzelx are reviewed under initial-therapy criteria.

    Patients with less than 6 months of therapy or who are restarting therapy are reviewed under initial-therapy criteria.

    Established for ≥3 months

    Patients with less than 3 months of therapy or who are restarting therapy are reviewed under initial-therapy criteria.

    • Hidradenitis suppurativa: the patient must have tried at least one other therapy.
    • Plaque psoriasis: the patient must have tried at least one traditional systemic agent for at least 3 months, unless intolerant, or have a contraindication to methotrexate. An exception may apply after a 3-month trial or prior intolerance to a qualifying biologic, Icotyde, Otezla/Otezla XR, or Sotyktu; the patient is not required to step back to a traditional systemic agent.
    • No indication-specific prior-treatment trial is stated for ankylosing spondylitis, non-radiographic axial spondyloarthritis, or psoriatic arthritis.
    Documentation Required

    Clinical Documentation Required

    Submit clinical documentation identifying the covered indication, whether therapy is initial or ongoing, patient age, required specialist prescriber or consultation, and all indication-specific medical-necessity details.

    • For initial therapy, document the applicable approval duration, age requirement, psychiatric risk evaluation, absence of moderately severe to severe depression, absence of the specified suicidal ideation or behavior history, and specialist prescribing or consultation.
    • For continuation therapy, document the duration of established Bimzelx use and the required response from baseline. Patients below the required treatment duration or restarting therapy are reviewed under initial-therapy criteria.
    • For non-radiographic axial spondyloarthritis, document objective inflammation; for plaque psoriasis, document prior systemic therapy, intolerance, or methotrexate contraindication as applicable.
    • Specialist requirements include rheumatology for ankylosing spondylitis and non-radiographic axial spondyloarthritis, dermatology for hidradenitis suppurativa and plaque psoriasis, and rheumatology or dermatology for psoriatic arthritis.
    Documentation Required

    Continuation Response Documentation

    For continuation requests, document the required minimum duration of prior Bimzelx therapy and indication-specific improvement from baseline before requesting renewal.

    • Ankylosing spondylitis, non-radiographic axial spondyloarthritis, and psoriatic arthritis: at least 6 months of therapy.
    • Hidradenitis suppurativa and plaque psoriasis: at least 3 months of therapy.
    • Document beneficial clinical response using an objective measure when required and improvement in at least one indication-specific symptom or functional outcome.
    Documentation Required

    Objective Inflammation Documentation

    For non-radiographic axial spondyloarthritis, provide objective evidence of inflammation with the request.

    • C-reactive protein elevated beyond the reporting laboratory's upper limit of normal; or
    • Sacroiliitis reported on magnetic resonance imaging.
    Documentation Required

    Prior-Treatment Documentation

    Document prior treatment for hidradenitis suppurativa and the required systemic-agent therapy or applicable exception for plaque psoriasis.

    • Hidradenitis suppurativa: document at least one prior therapy, such as intralesional or oral corticosteroids, systemic antibiotics, or isotretinoin.
    • Plaque psoriasis: document at least a 3-month trial of a traditional systemic agent, unless intolerant; a qualifying prior biologic, Icotyde, Otezla/Otezla XR, or Sotyktu trial or intolerance may provide an exception. A biosimilar of the requested biologic does not satisfy the exception.
    Denial Risk

    Concurrent Therapy Not Medically Necessary

    Do not administer Bimzelx concurrently with a biologic used for an inflammatory condition or with a targeted synthetic oral small-molecule drug. Such concurrent use is not medically necessary; conventional synthetic DMARDs are not excluded by this rule.

    • Examples of conventional synthetic DMARDs that may be used with Bimzelx include methotrexate, leflunomide, hydroxychloroquine, and sulfasalazine.
    Denial Risk

    Inflammatory Bowel Disease Exclusion

    Bimzelx for Crohn's disease, ulcerative colitis, or other inflammatory bowel disease is not medically necessary.

    • Exacerbations of inflammatory bowel disease, including serious exacerbations, occurred in clinical trials involving Bimzelx.
    Denial Risk

    Other Unapproved Uses Not Covered

    Bimzelx is not medically necessary for uses other than the five specified FDA-approved indications in this policy.

    • Covered indication categories are ankylosing spondylitis, hidradenitis suppurativa, non-radiographic axial spondyloarthritis, plaque psoriasis, and psoriatic arthritis.
    • The list of noncovered uses may not be all-inclusive and may be updated as new published data become available.
    Step Therapy

    Preferred-Product Requirement

    Before submitting the request, verify that the requested product satisfies Cigna's applicable preferred-product requirements and document any applicable exception under the referenced preferred specialty management policy.

    • Employer Plans: Standard/Performance, Value/Advantage, and Total Savings Prescription Drug Lists: refer to PSM001.
    • Individual and Family Plans: refer to PSM002.
    • Employer Plans: Legacy Prescription Drug Lists: refer to PSM017.
    Traditional systemic agent
    ExamplesMethotrexate, cyclosporine, or acitretin.
    PUVAA 3-month trial of psoralen plus ultraviolet A light (PUVA) also counts.
    Traditional systemic-agent trialFor plaque psoriasis, the trial is generally required for at least 3 months unless the patient is intolerant.
    The patient meets the applicable adult age requirement; according to the prescriber, the patient has been evaluated for risks of suicidal ideation or behavior versus benefits of therapy; the patient does not have moderately severe to severe depression; according to the prescriber, the patient has no history of suicidal ideation or suicidal behavior within the past 5 years; and the medication is prescribed by or in consultation with the required specialist.

    The required specialist is a rheumatologist for ankylosing spondylitis and non-radiographic axial spondyloarthritis; a dermatologist for hidradenitis suppurativa and plaque psoriasis; and a rheumatologist or dermatologist for psoriatic arthritis.